Century Therapeutics, INC 8-K filings

Century Therapeutics reported Q2 2026 results, highlighting progress on CNTY-813 for Type 1 Diabetes with a pre-IND meeting with the FDA and strong preclinical data, alongside advancing CNTY-308 for autoimmune diseases, supported by a cash runway into Q1 2029.

Century Therapeutics stockholders approved an increase in authorized common stock from 300 million to 450 million shares at the 2026 Annual Meeting.

Century Therapeutics announced new preclinical data for its iPSC-derived cell therapy, CNTY-813, demonstrating durable glucose control and immune evasion, advancing its potential as a functional cure for Type 1 Diabetes.

Century Therapeutics reported Q1 2026 financial results, highlighting progress in its type 1 diabetes and cancer cell therapies, with a cash runway extending into Q1 2029.

Century Therapeutics, Inc. filed a prospectus supplement for its existing at-the-market equity offering program, with $131.6 million remaining available for sale.

Century Therapeutics significantly reduced its net loss and extended its cash runway into 2029, driven by increased collaboration revenue and a successful $135 million private placement.

Century Therapeutics, Inc. announced it has regained compliance with Nasdaq's minimum bid price rule, leading to the decision not to proceed with a previously approved reverse stock split.

Century Therapeutics, Inc. provides an update on its iPSC-derived cell therapy pipeline, highlighting progress in Type 1 Diabetes and autoimmune diseases with its Allo-Evasion technology.

Century Therapeutics has secured an oversubscribed $135 million private placement to advance its lead Type 1 Diabetes program, CNTY-813, and extend its cash runway.

Dr. Carlo Rizzuto has resigned from the Board of Directors of Century Therapeutics, effective December 18, 2025, with no stated disagreements.

Century Therapeutics provides an update on its iPSC-derived cell therapy pipeline, highlighting progress in autoimmune diseases and Type 1 Diabetes, and extending its cash runway.

Century Therapeutics strengthens its Board of Directors with the appointment of Dr. Han Lee and Dr. Martin Murphy, bringing extensive financial and life science investment expertise.

Century Therapeutics announced its new iPSC-derived beta islet cell program for Type 1 diabetes, CNTY-813, alongside its Q3 2025 financial results and an extended cash runway into Q4 2027.

Century Therapeutics, Inc. has transferred its listing to The Nasdaq Capital Market after failing to meet the $1.00 minimum bid price requirement for The Nasdaq Global Select Market.

Century Therapeutics announced its second quarter 2025 financial results, provided a business update, and extended its cash runway into Q4 2027, alongside leadership changes.

Century Therapeutics, Inc. has announced a strategic workforce reduction of approximately 51% and the departure of its Chief Financial Officer and Chief Development Officer, aiming to refocus on high-potential programs.

Century Therapeutics, Inc. announced the successful election of Class I Directors and the ratification of Ernst & Young LLP as its independent auditor at its 2025 Annual Meeting of Stockholders.

Century Therapeutics reports first quarter 2025 financial results, highlighting patient dosing in the Phase 1 CALiPSO-1 trial and progress in preclinical programs.

Century Therapeutics is focusing its pipeline on four key programs and expects its cash to last into the fourth quarter of 2026.

Century Therapeutics received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement for continued listing.

Century Therapeutics reports a strong cash position of approximately $220 million as of December 31, 2024, and provides updates on its iPSC-derived allogeneic cell therapy pipeline.

Century Therapeutics and Bristol-Myers Squibb have terminated their research collaboration agreement, effective March 12, 2025, following a portfolio prioritization by BMS.

Century Therapeutics announced positive interim results from its Phase 1 trials of CNTY-101, expanded its autoimmune disease focus, and extended its cash runway into the second half of 2026 through organizational efficiencies.

Century Therapeutics has appointed Morgan Conn as its new Chief Financial Officer, effective October 14, 2024.

Century Therapeutics announced its second quarter 2024 financial results and provided updates on its clinical programs, including the initiation of a Phase 1 trial for autoimmune disease.

Century Therapeutics has released an updated investor presentation showcasing their advancements in iPSC-derived cell therapies, particularly their Allo-Evasion technology and clinical programs.

Century Therapeutics has acquired Clade Therapeutics, incorporating its assets and research into its operations.

Century Therapeutics held its 2024 Annual Meeting, electing three Class III directors, ratifying its accounting firm, and approving a certificate amendment to limit officer liability.

Century Therapeutics announced encouraging interim results from its Phase 1 ELiPSE-1 study of CNTY-101, showing a manageable safety profile and preliminary efficacy in relapsed or refractory non-Hodgkin lymphoma.

Century Therapeutics reported its Q1 2024 financial results, highlighted by a $60 million private placement and the acquisition of Clade Therapeutics, alongside advancements in their iPSC-derived cell therapy programs.